Literature DB >> 2842029

Histopathologic classification of small cell lung cancer. Changing concepts and terminology.

F R Hirsch1, M J Matthews, S Aisner, O Campobasso, J D Elema, A F Gazdar, B Mackay, M Nasiell, Y Shimosato, R H Steele.   

Abstract

Considerable attention has been devoted to the diagnosis of small cell lung carcinoma (SCLC) and its subtypes. In the literature contradictory opinions have been published concerning the clinical implications of subtyping, largely because of the different criteria used by different pathologists. This article is a consensus report by the Pathology Committee of the International Association for the Study of Lung Cancer. The following classification of SCLC is recommended: (1) Small cell carcinoma. This subtype includes most of the tumors previously included in the oat cell and intermediate subtypes. More than 90% of untreated SCLC fall into this category. (2) Mixed small cell/large cell carcinoma. This subtype, which may be associated with a poor prognosis and response to therapy, contains a spectrum of cell types ranging from typical SCLC to larger cells having prominent nucleoli and resembling large cell carcinoma. (3) Combined small cell carcinomas. Typical SCLC elements are intimately admixed with areas of differentiated squamous cell or adenocarcinoma. This simplified classification of SCLC will facilitate uniformity in the diagnosis and further our understanding of the clinical significance of the rarer SCLC with variant morphologies.

Entities:  

Mesh:

Year:  1988        PMID: 2842029     DOI: 10.1002/1097-0142(19880901)62:5<973::aid-cncr2820620521>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

Review 1.  The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies).

Authors:  W Theuer; O Selawry; K Karrer
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 2.  Pathogenesis of lung cancer: 100 year report.

Authors:  York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09       Impact factor: 6.914

Review 3.  Neuroendocrine differentiation in lung tumours.

Authors:  M N Sheppard
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

4.  Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder.

Authors:  Axel Bex; Remco de Vries; Floris Pos; Martijn Kerst; Simon Horenblas
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

5.  Surgery for combined type small cell lung carcinoma.

Authors:  R Hage; J R Elbers; A Brutel de la Rivière; J M van den Bosch
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

6.  Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit?

Authors:  Ahsan S Farooqi; Emma B Holliday; Pamela K Allen; Xiong Wei; James D Cox; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2017-01-07       Impact factor: 6.280

7.  (18)F-FDG PET in small-cell cervical cancer: a prospective study with long-term follow-up.

Authors:  Min-Yu Chen; Hung-Hsueh Chou; Feng-Yuan Liu; Chao-Yu Chen; Gigin Lin; Lan-Yan Yang; Yu-Bin Pan; Shih-Ming Jung; Ren-Chin Wu; Yi-Ting Huang; Jason Chien-Sheng Tsai; Tzu-Chen Yen; Chyong-Huey Lai; Ting-Chang Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-31       Impact factor: 9.236

8.  Unusual presentation of an uncommon lung malignancy.

Authors:  K Ramaraju; B Aggarwal; R Kulsrestha; Sk Chhabra
Journal:  Lung India       Date:  2008-07

9.  A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia.

Authors:  J J Quak; A J Balm; G A van Dongen; J G Brakkee; R J Scheper; G B Snow; C J Meijer
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

10.  Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Authors:  R M Przygodzki; S D Finkelstein; J C Langer; P A Swalsky; N Fishback; A Bakker; D G Guinee; M Koss; W D Travis
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.